Ticagrelor + Clopidogrel
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndrome
Conditions
Acute Coronary Syndrome, Coronary Artery Disease
Trial Timeline
May 1, 2013 → May 1, 2014
NCT ID
NCT01826175About Ticagrelor + Clopidogrel
Ticagrelor + Clopidogrel is a approved stage product being developed by AstraZeneca for Acute Coronary Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01826175. Target conditions include Acute Coronary Syndrome, Coronary Artery Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04069234 | Phase 3 | Withdrawn |
| NCT03437044 | Approved | Completed |
| NCT02617290 | Phase 3 | Completed |
| NCT02663713 | Approved | Completed |
| NCT02319941 | Phase 2 | Completed |
| NCT02457130 | Approved | UNKNOWN |
| NCT02379676 | Approved | UNKNOWN |
| NCT02121288 | Approved | Withdrawn |
| NCT02233790 | Approved | UNKNOWN |
| NCT02618733 | Pre-clinical | Completed |
| NCT02052635 | Approved | Terminated |
| NCT01826175 | Approved | Withdrawn |
| NCT01864005 | Approved | Completed |
| NCT01732822 | Phase 3 | Completed |
| NCT01706510 | Approved | Completed |
| NCT01603082 | Approved | Completed |
| NCT01523366 | Approved | Completed |
| NCT01523392 | Approved | Completed |
| NCT01118325 | Phase 2 | Completed |
| NCT00391872 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Coronary Syndrome